Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2022

Alhomoud M, Williams A, Magro C, Van Besien K, Vesole DH, Laurence J. Use of eculizumab in autologous hematopoietic stem cell transplantation-associated thrombotic microangiopathy in two adults. Leuk Lymphoma. 2022;63(2):473-477.

De La Vega LL, Comeau H, Sallan S, Al-Ibraheemi A, Gupta H, Li YY, et al. Rare FGFR Oncogenic Alterations in Sequenced Pediatric Solid and Brain Tumors Suggest FGFR Is a Relevant Molecular Target in Childhood Cancer. JCO Precis Oncol. 2022;6:e2200390.

Guo P, Liu Y, Geng F, Daman AW, Liu X, Zhong L, et al. Histone variant H3.3 maintains adult haematopoietic stem cell homeostasis by enforcing chromatin adaptability. Nat Cell Biol. 2022;24(1):99-111.

Liechty B, Xu Z, Zhang Z, Slocum C, Bahadir CD, Sabuncu MR, et al. Machine learning can aid in prediction of IDH mutation from H&E-stained histology slides in infiltrating gliomas. Sci Rep. 2022;12(1):22623.

Hsien S, Dayton JD, Chen D, Stock A, Bacha E, Cushing MM, et al. Hemostatic efficacy of pathogen-reduced platelets in children undergoing cardiopulmonary bypass. Transfusion. 2022;62(2):298-305.

Liao D, Geyer JT, Kacker A. Cervical Lymphadenopathy in an Elderly Man. JAMA Otolaryngol Head Neck Surg. 2022;148(7):686-687.

Bickett TE, Knitz MW, Piper M, Oweida AJ, Gadwa J, Darragh LB, et al. Dichotomous effects of cellular expression of STAT3 on tumor growth of HNSCC. Mol Ther. 2022;30(3):1149-1162.

Saliba M, Alzumaili BA, Katabi N, Dogan S, Tuttle RM, Zoltan A, et al. Clinicopathologic and Prognostic Features of Pediatric Follicular Cell-derived Thyroid Carcinomas: A Retrospective Study of 222 Patients. Am J Surg Pathol. 2022;46(12):1659-1669.

Kudalkar EM, Pang C, Haag MM, Pollyea DA, Kamdar M, Xu G, et al. 21q22 amplification detection in three patients with acute myeloid leukemia: cytogenomic profiling and literature review. Mol Cytogenet. 2022;15(1):30.

Xiang G, Wang S, Chen L, Song M, Song X, Wang H, et al. UBR5 targets tumor suppressor CDC73 proteolytically to promote aggressive breast cancer. Cell Death Dis. 2022;13(5):451.